STOCK TITAN

MediXall Group delays Q3 2026 financial report

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

MediXall Group, Inc. (MDXL) notified the SEC that its Form 10-Q for the period ended September 30, 2026, would be late and checked the Rule 12b-25 option to file on or before the fifth calendar day following the prescribed due date. The company said financial and other information needed for an accurate and complete report could not be provided on time without unreasonable effort or expense. It also reported delinquent 2024 and 2025 Forms 10-K and Forms 10-Q for the periods ended March, June and September 2025 and March and June 2026.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointDelinquent reports extended from 2024 through June 2026.

Filing Explained

MediXall checked “No” when asked whether the delayed quarter’s earnings statement was expected to show a significant change in operating results from the corresponding prior-year period; this is an expectation, not reported results.

Quarterly filing extension 5 calendar days The company checked the option to file on or before the fifth calendar day following the prescribed due date.
Rule 12b-25(b) regulatory
"relief pursuant to Rule 12b-25(b)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did MDXL expect a significant change in results in its delayed 2026 quarterly report?

No. MediXall indicated it did not anticipate a significant change in results of operations from the corresponding period for the last fiscal year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

       
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 
     
 
   
  FORM 12b-25

SEC FILE NUMBER

333-194337

  NOTIFICATION OF LATE FILING

CUSIP NUMBER

 

 

                             
(Check one):  Form 10-K     Form 20-F     Form 11-K  ü   Form 10-Q     Form 10-D     Form N-CEN     Form N-CSR

 

         
  For Period Ended:  September 30, 2026
     
     Transition Report on Form 10-K
     
     Transition Report on Form 20-F
     
     Transition Report on Form 11-K
     
     Transition Report on Form 10-Q
     
  For the Transition Period Ended:  
     

 

 
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION

 

 
MediXall Group, Inc.
Full Name of Registrant
 
 
Former Name if Applicable
 
104 N 4th St.
Address of Principal Executive Office (Street and Number)
 
Leesburg, FL 34748
City, State and Zip Code

 

 

 
 
 

 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

           
        (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
ü
 
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 
PART III — NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
 
Certain financial and other information necessary for an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort or expense.

 

 
PART IV — OTHER INFORMATION

 

                   
(1) Name and telephone number of person to contact in regard to this notification
 
  Travis Jackson   800   381-1787
  (Name)   (Area Code)   (Telephone Number)
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes    No  ü  
 

 

The Company is delinquent in filing the 2024 Form 10-K, the Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025; the 2025 Form 10-K, and the Form 10-Q for the periods ended March 31, 2026 and June 30, 2026. We are in the process of preparing the respective Form 10-K’s and Form 10-Q’s for filing with the Securities and Exchange Commission.

 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes    No  ü  
 
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.  
 

 

           
   
  MediXall Group, Inc.
  (Name of Registrant as Specified in Charter)
   
  has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
   
Date: November 16, 2026     By: /s/ Travis Jackson
          Travis Jackson, Chief Financial Officer
             

 

Keep reading